Revenue FY2025
$6.22B
Net Income
$0.19B
EPS (Basic)
$0.72
Net Margin
3.0%
ROE
24.9%
Total Equity
$0.75B
Shares Out
263M
Organon & Co. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 2 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
Kahn Brothers Group
Kahn Brothers
$36.2M
7.4%
(51.8%)
Royce & Associates
Royce & Associates
$1.3M
0.0%
—
Insider Transactions
Reading stored insider transactions…